The subcutaneous formulation of Opdivo provides a convenient alternative to intravenous administration for patients with solid tumors, maintaining efficacy and safety. The CHECKMATE-67T trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback